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Topic: Prehospital use of ipratropium bromide paired with salbutamol as treatment for shortness of breath.
Clinical Scenario: Two primary care paramedics respond code 4 for a 55 year old male patient severely short of breath. Questioning
his wife reveals that the patient has chronic obstructive pulmonary disease (COPD), takes Ventolin (salbutamol) when necessary and
takes Atrovent (ipratropium bromide) daily. He took his Atrovent today, but experienced sudden onset shortness of breath after
walking up the flight of stairs in his home.
PICO Question: In patients with shortness of breath from respiratory diseases, does the use of prehospital ipratropium bromide paired
with salbutamol provide a better outcome than salbutamol treatment alone?
Search Strategy: see Appendix 1
Relevant Papers: eight relevant articles were found, but four were reviewed because they were most directly related to the topic
Key Words: FVC: forced vital capacity, amount of air which can be forcibly exhaled from the lungs after taking a full breath in
FEV1: forced expiratory volume, volume of air exhaled in one second of forced expiration
ED: emergency department
COPD: chronic obstructive pulmonary disease
COAD: chronic obstructive airway disease
Author,
Date
Davis, D.,
2005

Population

Design

371 adult
Prehospital
patients, 18
retrospective
years of age
study
or older,
transported to
the
University of
California
ED and
treated for
suspected
reactive

Outcomes

Results

Strengths/Weaknesses

•

Avg. change in vital signs,
Albuterol alone cohort
(n=192)
• ∆HR: -3 bpm
• ∆BP: -7mmHg
• ∆resp. rate: 0
• ∆SaO2: +8%
• Improved clinical status:
34% of pts
Avg. change in vital signs,
Albuterol/Ipratropium cohort
(n=179)

Strengths
Used vitals as an objective
way to obtain data of patient
improvement. Fairly large
sample size. Study could be
reproduced in other regions.

•

Change in
heart rate,
respiratory
rate, blood
pressure
and/or oxygen
saturation.
Clinical
improvement
or
deterioration

Weaknesses
Retrospective design, so
patients were not
randomized to receive each
treatment. Data relies on

airway
disease
(RAD). Pts
were treated
with either
nebulized
albuterol and
ipratropium
bromide or
just albuterol.

Author,
Date
Moayyedi,
P., 1995

Population

as assessed by
paramedics.

•
•
•
•
•

∆HR: -6 bpm
∆BP: -10mmHg
∆resp. rate:
-4 breaths/min
∆SaO2: +8%
Improved clinical status:
33% of pts

There was no statistically
significant difference, p-value
< 0.05, between groups.

Design

62 patients
Randomized
admitted to
controlled
hospital for
trial
acute
exacerbation
of COPD. Pts
treated with
either 5mg
nebulized
salbutamol and
500µg
ipratropium
bromide, or
just 5mg
salbutamol,
both four times
a day.

past EMS and ED records.
Approximately one third of
patients included in study
were diagnosed with a
cardiac etiology for their
dyspnea. Analyzing
treatment effect during short
prehospital transport times
does not indicate the longerterm effects.

Outcomes

Results

Strengths/Weaknesses

•

Mean change in FEV1
Salbutamol only
• Day 1 – 3: +0.17 mL
• Day 1 – 7: +0.21 mL
• Day 1 – 14: +0.06 mL
• Discharge: +0.23 mL
Mean change in FVC
Salbutamol only
• Day 1 – 3: +0.25 mL
• Day 1 – 7: +0.39 mL
• Day 1 – 14: +0.33 mL
• Discharge: +0.56 mL
Mean change in FEV1
Salbutamol + ipratropium
bromide
• Day 1 – 3: +0.05 mL
• Day 1 – 7: +0.15 mL
• Day 1 – 14: +0.26 mL

Strengths
Examines changes over
time to get a better picture
of the long-term effects of
the two treatments.
Extensive exclusion
criteria to ensure minimal
confounding variables.
Spirometric values
obtained at 1800 hrs each
time.

•

•

Change in
spirometric values
(forced vital
capacity and
FEV1) on days 1,
3, 7, 14 and then
weekly and on the
day of discharge.
Simple subjective
symptom score
recorded daily. Pts
asked to report
whether they feel
better, worse, or
the same as the
day before.
Duration of
hospital stay.

Weaknesses
Small sample size, also
restricted to patients with
COPD.
Some patients did receive
other IV steroid and

All pts were
not taking
nebulized
bronchodilator
s at home,
were 45 years
of age or older,
and had a
history of
smoking more
than 10 pack
years.
Author, Date
Koutsogiannis,
Z., 2000

Population
50 adult patients
admitted to the
emergency
department with
COAD. Pts
received 5mg
nebulized
salbutamol and
500µg
ipratropium
bromide and
250mg IV
hydrocortisone at
time=0. Then
randomized to
receive 5mg
salbutamol and
500µg
ipratropium

•

Numbers of days
on nebulizer
treatment.

• Discharge: +0.15 mL
Mean change in FVC
Salbutamol + ipratropium
bromide
• Day 1 – 3: +0.04 mL
• Day 1 – 7: +0.17 mL
• Day 1 – 14: +0.62 mL
• Discharge: +0.42 mL

antibiotic medication, but
study states there was no
statistically significant
difference between groups.

No statistically significant
difference, p <0.05
between groups.
Design
Outcomes
Prospective, • Mean
randomised,
percent
double
change in
blind trial
FEV1
measured at
time=0 and
time=90
mins.
• Absolute
change on
pulmonary
function test

Results
Mean percentage
change in FEV1
• comb. treatment:
6.4%
• salbutamol:
18.6%
• ipratropium:
4.8%
Mean absolute
change on
pulmonary function
test
• comb. treatment:
0.06L
• salbutamol:
0.13L
• ipratropium:
0.023L

Strengths/Weaknesses
Strengths
Different perspective
considering ipratropium bromide
was given to both groups as an
initial treatment, then studied
subsequent treatments of
ipratropium.
Explains the cost of ipratropium
bromide and the seemingly
minimal benefits when paired
with salbutamol in the
prehospital environment.
Weaknesses
Small sample size and only one
diagnostic tool used for
comparison of improvement.
Standard deviation in absolute
change in FEV1 is large in all

bromide, or 5mg
salbutamol alone,
or 500µg
ipratropium
bromide alone, at
15min and 30min.
Author,
Date
Lanes, S.F.,
1998

No statistically
groups, suggesting there are
significant difference subgroups within the sample that
between groups.
may benefit from the combined
treatment.

Population

Design

Outcomes

Results

Strengths/Weaknesses

1064 pts aged
18 to 55 years
admitted to the
emergency
department
with acute
asthma. Pts
randomized for
treatment of a
combination of
nebulized
2.5mg
salbutamol
plus 0.5mg
ipratropium
bromide, or
2.5mg
salbutamol
alone.

Pooled
analysis of
three
randomized
doubleblinded
clinical trials
conducted in
the United
States,
Canada and
New
Zealand.

•

Mean difference between
FEV1 change from time=0

Strengths
Account for all
differentiating factors in
the populations studied.
Extensively explains and
accounts for all study
biases, including the
original claims of each of
the studies, which did not
coincide with the overall
conclusions when
looking at all three
studies.
Weaknesses
Outcome of seemingly
positive effects of the
combination treatment
was <10% of the overall
improvement of FEV1
from baseline, indicating
only a small
improvement. Also stated
that the data could be

•

FEV1 measured
at baseline, 45
mins and 90
mins. Pts
followed up for
48h after
hospital
discharge for
occurrence of
asthma
exacerbation
and
hospitalization.
Reduced risk of
need for
additional
treatment,
subsequent
asthma
exacerbations
and
hospitalizations

Ipratropium + salbutamol
45 minutes
• CAN: 587mL
• NZ: 461mL
• US: 651mL
90 minutes
• CAN: 633mL
• NZ: 519mL
• US: 831mL
Salbutamol
45 minutes
• CAN: 542mL
• NZ: 369mL
• US: 645mL
90 minutes
• CAN: 542mL
• NZ: 416mL
• US: 851mL

Small improvement in lung
function indicated for
combination treatment.

obscured by outliers in
the U.S.A. study.

Comments:
One major challenge that presents with this PICO question is the specificity of observing prehospital, emergency medicine data of the
benefits of pairing ipratropium bromide and salbutamol. None of the studies analyzed in this CAT occurred within the last 10 years,
and took place in either the emergency department or longer in-hospital stays. Moayyedi et al. completed their study over several days
until patient discharge, evaluating FEV1 and FVC, as well as some subjective symptom questions (1995). This prospective study
produced no statistically significant difference between treatment groups, further suggesting that ipratropium bromide paired with
salbutamol does not give any additional benefit to patients with SOB due to airway diseases. Contraindicative to these results, Lanes et
al. examine FEV1 at 0 mins, 45 mins, and 90 mins after arrival in the ED (1998). A small improvement was noted for patients who
received the combination treatment, as well as reduced risk for subsequent symptoms of asthma. The large total sample size and crosscountry meta-analysis study design enhances the efficacy of the results and the ability to detect small differences in data (Lanes et al.
1998). Only one of the studies mentioned a reason for questioning the effect of the combination treatment. The cost of using a
medication that does not seem to have significant benefit in prehospital treatment, is a factor to consider because that money can be
put towards something else. Emergency medicine in Canada is always in need of improvements in equipment, education, community
programs, and many other things. Though the cost of PCPs using ipratropium bromide may seem small, the savings of not using it
over a year could have a significant benefit to another aspect of paramedicine. There is also always a risk of patients having adverse
reactions to medications. So if the latest evidence-based medicine shows little to no benefit of the pairing of ipratropium bromide and
salbutamol in the prehospital environment, it should be considered to be removed from PCP scope of practice.
Consider: Why would you NOT change practice, based on these articles?
Since these studies mainly look at short term treatment of ipratropium bromide and salbutamol, the long term effects of the
combination is not well observed. Perhaps continuous treatment of the paired medications has a significant effect in patient
presentation after several weeks. The use of the combination treatment in the prehospital environment could be beneficial for patients
who are going to be prescribed these two medications and will be using them consistently from that point forward. Using it to treat
these critical patients will theoretically begin their treatment at the earliest moment possible.

Clinical Conclusion:
The use of ipratropium bromide for shortness of breath due to chronic airway diseases, appears to be of little additional benefit than
salbutamol treatment alone, in the prehospital environment. Paramedics should perhaps consider the costs of using the drugs paired
together when deciding what to use to treat SOB. Salbutamol alone is a very effective way to dilate bronchioles, enhance ventilation
and allow for reperfusion in a short period of time.

Appendix 1
S1
S2
S3
S4
S5
S6
S7
S8
S9
S10
S11
S12
S13
S14
S15
S16

Key Word
Ipratropium bromide/albuterol
Albuterol/ipratropium bromide
Ipratropium bromide/salbutamol
Salbutamol/ipratropium bromide
Salbutamol
Albuterol
Ipratropium bromide
Prehospital
Pre hospital
Pre-hospital
Out of hospital
S1 OR S3
S5 OR S6
S8 OR S9 OR S10 OR S11
S12 AND S13 AND S14 AND S7
S14 AND S7

Results (CINAHL & EBSCO)
246
22
173
17
318
1363
160
11606
1114
710
5582
249
1486
17160
1
52

Back-sourcing used
Nova Scotia EHS: Canadian Prehospital Evidence-Based Practice website used
https://emspep.cdha.nshealth.ca/LOE.aspx?VProtStr=Asthma&VProtID=200

Results (MEDLINE)
626
422
689
689
11492
10061
2233
9338
38437
3279
95408
724
12220
136985
9
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